OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study.

Plast Reconstr Surg · 2026 · PMC13290051 · PMID 41329600

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend was observed over subsequent cycles, and only 37% of the participants had severe platysma prominence on both sides before treatment cycle 4 (Table 2 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.